Taysha Gene Therapies, Inc. Segment Reporting Other Item Amount
Taysha Gene Therapies, Inc. (TSHA) reported Segment Reporting Other Item Amount of $3.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-11
- Taysha Gene Therapies, Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $3.04M, a 52.37% decline year-over-year.
- Taysha Gene Therapies, Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $4.67M, a 12.81% decline year-over-year.
- Taysha Gene Therapies, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $4.95M, a 54.26% increase year-over-year.
- Taysha Gene Therapies, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was $4.34M, a 55.20% decline year-over-year.
- Taysha Gene Therapies, Inc. segment reporting other item amount for fiscal 2025 was $21.03M, a 1.79% decline from fiscal 2024.
- Taysha Gene Therapies, Inc. segment reporting other item amount for fiscal 2024 was $21.41M, a 64.47% decline from fiscal 2023.
- Taysha Gene Therapies, Inc. segment reporting other item amount for fiscal 2023 was $60.26M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.04M 10-Q · filed 2026-08-11 | $7.71M 10-Q · filed 2026-08-11 | $12.65M derived: sum of 3 quarters · filed 2026-08-11 | $17.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.67M 10-Q · filed 2026-05-06 | $9.62M derived: sum of 2 quarters · filed 2026-05-06 | $13.96M derived: sum of 3 quarters · filed 2026-05-06 | $20.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $9.29M derived: sum of 2 quarters · filed 2026-03-19 | $15.67M derived: sum of 3 quarters · filed 2026-08-11 | $21.03M 10-K · filed 2026-03-19 |
| 2025-09-30 | $4.34M 10-Q · filed 2025-11-04 | $10.72M derived: sum of 2 quarters · filed 2026-08-11 | $16.08M 10-Q · filed 2025-11-04 | $19.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $6.38M 10-Q · filed 2026-08-11 | $11.74M 10-Q · filed 2026-08-11 | $14.94M derived: sum of 3 quarters · filed 2026-08-11 | $24.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $5.35M 10-Q · filed 2026-05-06 | $8.56M derived: sum of 2 quarters · filed 2026-05-06 | $18.25M derived: sum of 3 quarters · filed 2026-05-06 | $22.62M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $12.90M derived: sum of 2 quarters · filed 2026-03-19 | $17.27M derived: sum of 3 quarters · filed 2026-03-19 | $21.41M 10-K · filed 2026-03-19 |
| 2024-09-30 | $9.69M 10-Q · filed 2025-11-04 | $14.06M derived: sum of 2 quarters · filed 2025-11-04 | $18.20M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $4.36M 10-Q · filed 2025-08-12 | $8.51M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $4.14M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $60.26M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |